Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Aura Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216808
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating Expenses: | ||
| Research and development | $27,960 | $23,343 |
| General and administrative | 6,906 | 5,692 |
| Total operating expenses | 34,866 | 29,035 |
| Total operating loss | (34,866) | (29,035) |
| Other income (expense): | ||
| Interest income, including amortization and accretion income | 1,190 | 1,594 |
| Other income (expense) | 2 | (24) |
Item 1. Financial Statements.
FAQ
- What is Aura Biosciences, Inc.'s R&D?
- Aura Biosciences, Inc. (AURA) reported R&D of $27.96M in Q1 2026.
- How has Aura Biosciences, Inc.'s R&D changed year-over-year?
- Aura Biosciences, Inc.'s R&D increased by 19.8% year-over-year, from $23.34M to $27.96M.
- What is the long-term trend for Aura Biosciences, Inc.'s R&D?
- Over 4 years (2021 to 2025), Aura Biosciences, Inc.'s R&D has grown at a 37.6% compound annual growth rate (CAGR), from $25.16M to $90.3M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Aura Biosciences, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude